ALK and non-small cell lung carcinoma: Nevertheless, it should be pointed out that the updated 2017 guidelines from The American Society of Clinical Oncology (ASCO) recommends crizotinib for first-line therapy of Stage IV NSCLC with a confirmed ALK rearrangement [99].